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The terai malaria originates from Medieval Italian: mala aria - 'bad air'; and the disease 
was formerly called 'ague' or marsh fever due to its association with swamps. Malaria 
has been known from antiquity, the earliest information came from ancient Egypt and 
various Papyri. The first accurate clinical description of malaria was given by 
Hippocrates in 400 BC (Boyd 1949), who mentioned the classic triad of chills, fever 
and sweating and analyzed the characteristic periodicity of various phases of malaria. 
Malaria is one of the world's most common diseases, caused by protozoan parasites 
belonging to the genus Plasmodium and is an infectious disease. It is one of the six 
diseases included in WHO special programme, is causing a lot of morbidity and 
mortality all around the world. Malaria is prevalent in humid tropics between latitude 
45° N and 45° S mainly in Africa, Asia and Central and South America. Over 40% 
population of the world is exposed to the risk of malaria. Malaria is a major burden for 
the most resource-poor nations of the world. Malaria is considered the world's most 
important fropical parasitic disease. Approximately 300-500 million clinical cases are 
recorded every year in the world. Each year malaria kills approximately one million 
people worldwide, 90% of which are living in sub-Saharan Africa. The large majority 
of the victims are pregnant mothers and children under the age of 5 (World Malaria 
Report 2005, WHO). Around 107 countries in the worid are affected by malaria, with 
almost half of them located in Africa, South of Sahara and around 3.2 billion people 
are at risk of acquiring the infection. It has been estimated that malaria kills 
approximately 3000 children every day only in Africa (Phillips, 2001). 
Among member countries of South East Asian Region Office (SEARO) of WHO, 
India contributes >85% cases annually. There are about 2.5 to 3 million reported cases 
and 1000 deaths each year due to malaria (WHO, 2003). These malaria cases were 
highly under-reported. The estimates of WHO indicate about 81 million cases 
(Korenromp, 2004). 
Historically, malaria has been a problem in India for centuries. Malaria is endemic in 
India with varying levels of endemicity. Most regions in the country have an unstable 
malaria situation except in the North-Eastern region where stable malaria situation 
prevails. Situation of malaria in India till 1950's was very serious, with over 75 million 
cases and 0.8 million deaths every year. Keeping grave situation of malaria in view. 
National Malaria Control Programme (NMCP) was started in 1953 and encouraging 
results were obtained. Later on after 5 years National Malaria Eradication Programme 
(NMEP) was launched in 1958, which resulted in dramatic decrease in malaria cases. 
In 1965, cases came down to 0.1 million with no death record. Euphoria of success was 
so overwhelming that malaria was considered as a disease of past. Resurgence of 
malaria occurred in 1970 because of administrative, financial and technical failure 
(Sharma and Mehrotra, 1986). In 1990s malaria re-emerged and took the lives of 
several thousand people (Sharma, 1996). Factors responsible for the re-emergence of 
malaria were vector resistance to insecticide and parasite's resistance to drug. 
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(Drugs against malaria act at different stages of the parasite lite cycle. Blood 
schizontocidal drugs (suppressive or clinical) attack parasite in erythrocyte, preventing 
or ending clinical attack. Gametocytocidal drugs destroy sexual forms in human, 
decreasing transmission. Tissue schizonticidal drugs act on early stages of parasite 
development in liver, betbre the release of merozoites into blood. Hypnozoitocidal 
drugs kill dormant hypnozoites in liver, preventing relapses of infection. Finally, 
sporontocidal drugs inhibit development of oocysts in mosquito, decreasing malaria 
transmission. The choice of malaria treatment is first of all influenced by what type of 
species cause the infection. Some species rarely have chloroquine resistance (e.g. 
P. vivca) or they have a hypnozoite stage that is only eradicated by primaquine or 
tafenoquine. The parasite sensitivity is a very important factor to consider. It is well 
known today that P. falciparum has evolved multi-drug resistance in many parts of the 
world. Another factor, that may influence the drug choice, is the host's degree of 
immunity. Some classes of drug are acceptable for the treatment of "semi-immune" 
patients, but "unacceptable" for non-immunes. Finally, risk-benefit analysis of drug 
adverse effects and treatment potentials should be always made prior to any therapy 
initiation. 
i i ^ H , Socro^it^ 
'*•'Zygote 
6ofnetocytes 
GAMICnOCISALIIRliGS 
Pmt:iaqim ^taftr^Mtf (all), 
fiMcklUlld?(P,V',Pi>..P.7J3,) 
< • 
BLOOD KHBtimCDALMUCiJ 
Quinine, in^flcqiuns. cUoroqine, 
tio'i'^uoii^, aitenusiiuits, 
IftracjiiclmK, clmtUmycm, 
laffrioquuif 
Er/throcylic 
vcic 
o 
SIORDKTOCISALDRUCIS 
HI 
$ 
HepN3.ii<;cyde 
HYFTfOZOITOriML SRl'GS 
PriiMquinie, lafenoquii* 
nssvE uuzoimcniAL m v c s 
P j M i i M , laiffioquM, picq^MiL 
Action of Antimalarials 
CHLOROQUINE: 
Description: 
Chloroquine is a 4-aminoquinoline compound. It is an antimalarial and amebicidal 
drug. Chemically, it is 7- chloro-4-[4- (diethylamino) - 1 - methylbutyl]amino] 
quinoline phosphate (1:2) 
Chemical Formula: CgHjeClNs; Molecular Mass: 319.872 g/mol 
Chemistry & Pharmacokinetics: Chloroquine is a synthetic 4-aminoquinoline 
formulated as the phosphate salt for oral use. It is rapidly and almost completely 
absorbed from the gastrointestinal tract, reaches maximum plasma concentrations in 
about 3 hours, and is rapidly distributed to the tissues. Chloroqume is principally 
excreted in the urine with an initial half-life of 3-5 days but a much longer terminal 
elimination half-life of 1-2 months. 
Antimalarial Action: Chloroquine is a highly effective blood schizonticide and 
remains the principal antimalarial drug in most part of the world. It is also moderately 
effective against gametocytes of P. vivca, P. ovale, and P. malariae but not against 
those of P. falciparum._ 
Mechanism of Action: The mechanism of action remains controversial. Chloroquine 
probably acts by concentrating in parasite food vacuoles, preventing the polymerization 
of the hemoglobin breakdown product, heme, into hemozoin and thus eliciting parasite 
toxicity due to the buildup of free heme. 
Resistance: Resistance to chloroquine is now very common among strains of P. 
falciparum and uncommon but increasing for P. vivax. 
Treatment: Chloroquine is the drug of choice for the treatment of non falciparum and 
sensitive falciparum malaria. 
Chemoprophylaxis: Chloroquine is the preferred chemoprophylactic agent in 
malarious regions without resistant falciparum malaria. Eradication of P. vivax and P. 
ovale requires a course of primaquine to clear hepatic stages. 
Adverse Effects: Pruritus is common, primarily in Africans. Nausea, vomiting, 
abdominal pain, headache, anorexia, malaise, blurring of vision, and urticaria are 
uncommon. 
AMODIAQUINE: 
Amodiaquine has been widely used to treat malaria in many countries because of its 
low cost, limited toxicity, and, in some areas, effectiveness against chloroquine-
resistant strains of P. falciparum. 
Chemical Formula: C20H22CIN3O; Molecular Mass: 355.861 g/mol 
Clinical Pharmacology: Amodiaquine is an antimalarial with schizonticidal activity. It 
is effective against the erythrocytic stages of all 4 species of Plasmodium. It is as 
effective as chloroquine against chloroquine-sensitive strains of P. falciparum and is 
also effective against some chloroquine-resistant strains. 
Pharmacokinetics: Amodiaquine hydrochloride is readily absorbed from 
gastrointestinal tract. Amodiaquine is rapidly converted in the liver to the active 
metabolite desethylamodiaquine. Only a negligible amount of amodiaquine is being 
excreted unchanged in the urine. The plasma elimination half-life of 
desethylamodiaquine has varied from 1 to 10 days. 
Adverse effects: Agranulocytosis and other blood dyscrasias, hepatitis and peripheral 
neuropathy have been reported occasionally after amodiaquine usage alone. 
In therapeutic doses used for malaria, amodiaquine may occasionally cause nausea, 
vomiting, diarrhoea, vertigo and lethargy. Abdominal pain, headache and 
photosensitivity have been reported with amodiaquine. 
QUININE & QUINIDINE: 
Quinine and quinidine remain first-line therapies for falciparum malaria. Resistance to 
quinine is uncommon but increasing. 
Chemical Formula: C20H24N2O2; Molecular Mass: 324.417 g/mol 
Antimalarial Action: Quinine is a rapidly acting, highly effective blood schizonticide 
against the four species of human malaria parasites. The drug is gametocidal against 
P. vivax and P. ovale but not P. falciparum. It is not active against liver stage 
parasites. The mechanism of action of quinine is unknown. 
Resistance: Increasing in vitro resistance of parasites from a number of areas suggests 
that quinine resistance will be an increasing problem in the future. 
Clinical Uses: 
Parenteral treatment of severe falciparum malaria, oral treatment of falciparum malaria, 
malarial chemoprophylaxis 
Adverse Effects: Tinnitus, headache, nausea, dizziness, flushing, and visual 
disturbances, a constellation of symptoms termed cinchonism. Severe hypotension can 
follow too-rapid intravenous infusions of quinine or quinidine. 
MEFLOQUINE: 
It is a 4-quinolinemethanol derivative with the specific chemical name of [2, 8 - bis 
(trifluromethyl) quinolin-4-yl] - (2-piperidylmethanol). It is a 2-aryl substituted 
chemical structural analog of quinine. 
Chemical Formula: C17H16 F6N2O; Molecular Mass: 378.312 g/mol 
Chemistry & Pharmacokinetics: Mefloquine hydrochloride is a synthetic 4-quinoline 
methanol that is chemically related to quinine. It can only be given orally because 
severe local irritation occurs with parenteral use. It is well absorbed, and peak plasma 
concentrations are reached in about 18 hours. Mefloquine is highly protein-bound, 
extensively distributed in tissues, and eliminated slowly, allowing a single-dose 
treatment regimen. The terminal elimination half-life is about 20 days, allowing weekly 
dosing for chemoprophylaxis. 
Antimalarial Action: Mefloquine has strong blood schizonticidal activity against 
P. falciparum and P. vivax, but it is not active against hepatic stages or gametocytes. 
The mechanism of action of mefloquine is unknown. 
Resistance: Sporadic resistance to mefloquine lias been reported from many areas. At 
present, resistance appears to be uncommon except in regions of Southeast Asia with 
high rates of muhidrug resistance. 
Treatment: Mefloquine is effective in treating most falciparum malaria, but the drug 
has not been approved by the FDA for this purpose. The drug is not appropriate for 
treating individuals with severe or complicated malaria 
PRIMAQUINE: 
Primaquine is the drug of choice for the eradication of dormant liver forms of P. vivax 
and P. ovale. Primaquine, an 8-aminoquinoline derivative, is a synthetic antimalarial 
agent. Its chemical formula is (R,S)-N''-(6-Methoxy-8-quinoIinyl)-l,4-pentanediamine 
diphosphate. 
Chemical Formula: C15H21N3O.2H3PO4: Molecular Mass: 259.347 g/mol 
Antimalarial Action: Primaquine is active against hepatic stages of all human malaria 
parasites. It is the only available agent active against the dormant hypnozoite stages of 
P. vivax and P. ovale. 
Resistance: Some strains of P. vivax in New Guinea, Southeast Asia, and perhaps 
Central and South America are relatively resistant to primaquine. Liver forms of these 
strains may not be eradicated by a single standard treatment with primaquine. 
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Clinical Uses: 
Therapy (Radical Cure) of acute vivax and ovale malaria, terminal prophylaxis of 
vivax and ovale malaria, chemoprophylaxis of malaria. 
Adverse Effects: Nausea, epigastric pain, abdominal cramps, and headache, and these 
symptoms are more common with higher dosages and when the drug is taken on an 
empty stomach. 
ARTEMETHER: 
Chemistry: 
Artemether is a lipid soluble methylether of dihydroartemisinin. Artemisinin is a novel 
sesquiterpene lactone, extracted from the leaves of the shrub Artemesia annua 
Its chemical formula is 3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-
3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-l,2-benzodioxepin. 
Chemical formula: C16H26O5; Molecular Mass: 298.4 g/mol 
Clinical Pharmacology: Artemether is active against all Plasmodia including those 
which may be resistant to other antimalarials. Artemether has very rapid schizontocidal 
activity. It is not hypnozoiticidal but it reduces gametocyte carriage 
Pharmacokinetics: Pharmacokinetic data in humans are sparse, with no data 
demonstrating the rate or extent of absorption or the systemic distribution of artesunate. 
After parenteral administration, artesunate is rapidly hydrolyzed to the active 
metabolite dihydroartemisinin. The oral formulation is probably hydrolysed completely 
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before entering the systemic circulation. Peak serum levels occur within one hour of an 
oral dose of artesunate and persist for up to 4 hours. 
Adverse effects: Artemether has been remarkably well-tolerated, and appears less 
toxic than quinine or chloroquine; adverse effects include bradycardia, 
electrocardiogram abnormalities, gastrointestinal disturbances (nausea, abdominal pain, 
diarrhoea - oral therapy only), dizziness, injection site pain, skin reactions, and fever. 
PYRIMETHAMINE: 
Pyrimethamine (Daraprim®) is a medication used for protozoal infections. It is 
commonly used as an antimalarial drug (for both treatment and prevention). 
Mechanism of Action: Pyrimethamine interferes with folic acid synthesis by inhibiting 
the enzyme dihydrofolate reductase. Folic acid is needed for DNA and RNA synthesis 
in many species, including protozoa. 
Mechanism of resistance: Resistance to pyrimethamine is widespread. Mutations in 
the gene for dihydrofolate reductase may reduce the effectiveness of pyrimethamine. 
These mutations decrease the binding affinity between pyrimethamine and 
dihydrofolate reductase by steric interactions 
Clinical Use: Pyrimethamine is typically given with a sulfonamide and folinic acid: 
Sulfonamides inhibit dihydropteroate synthetase, an enzyme that participates in folic 
acid synthesis from para-aminobenzoic acid. Hence, sulfonamides work synergistically 
with pyrimethamine by blocking a different enzyme needed for folic acid synthesis. 
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Adverse effect: Pyrimethamine may deplete folic acid in humans, resulting in 
hematologic side effects associated with folate deficiency, megaloblastic anemia, 
leukopenia, pancytopenia, atrophic glossitis, hematuria, cardiac arrhythmias, 
pulmonary eosinophilia (rare). 
F ANSID AR (P YRIMETH AMINE/SULF ADOXINE) : 
Description: 
Fansidar is an antimalarial agent, each tablet containing 500 mg Nl-(5, 6- dimethoxy -
4- pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2, 4- di amino - 5-(P-
chlorophenyl) - 6-ethylpyrimidine (Pyrimethamine). 
Mechanism of Action: 
Sulfadoxine and Pyrimethamine, the constituents of Fansidar, are folic acid 
antagonists. Sulfadoxine inhibits the activity of dihydropteroate synthase whereas 
Pyrimethamine inhibits dihydrofolate reductase. 
Activity in vitro: Sulfadoxine and Pyrimethamine are active against the asexual 
erythrocytic stages of Plasmodium falciparum. Fansidar may also be effective against 
strains of Plasmodium falciparum resistant to chloroquine. 
Drug Resistant: Strains of Plasmodium falciparum with decreased susceptibility to 
Sulfadoxine and /or Pyrimethamine can be selected in vitro or in vivo. Plasmodium 
falciparum malaria that is clinically resistant to Fansidar occurs frequently in parts of 
South Asia and South America, and is also prevalent in East and central Africa. 
Therefore, Fansidar should be used with caution in these areas. Likewise, Fansidar may 
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not be effective for treatment of recrudescent malaria that develops after prior therapy 
(or prophylaxis) with Fansidar. 
ARTESUNATE: 
Chemical Formula: C16H2605; Molecular Mass: 384.421 g/mol 
Pharmacokinetics & Chemistry: Pharmacokinetic data in humans are sparse, with no 
data demonstrating the rate or extent of absorption or the systemic distribution of 
Artesunate. After parenteral administration, Artesunate is rapidly hydrolyzed to the 
active metabolite dihydroartemisinin. The oral formulation is probably hydrolysed 
completely before entering the systemic circulation. Peak serum levels occur within 
one hour of an oral dose of Artesunate and persist for up to 4 hours. 
Adverse effects: Artesunate and other related Artemisinin derivatives have been 
widely used in China, with no reports of any serious adverse reactions. Drug induced 
fever can occur. 
14 
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^e field of toxicology deals with effects of living systems, with the purpose of 
defining human health effects. It is an applied science, which draws on data and 
methodology from a multitude of basic sciences, such as physiology, pharmacology, 
the study of metabolism, ethology, genetics, embryology, chemistry, and statistics. 
Animal models are generally used as human surrogates in toxicologic evaluations. 
Animal models are bioassays that involve the use of a species believed to exhibit a 
toxic response similar to that of humans under exposure conditions relevant to human 
exposures. Mammals are the most common test organisms employed. The study of 
animal toxicology may be divided into many subspecialities include 
metabolism/pharmacokinetics, genetic toxicology, reproduction/teratology, 
immunotoxicology, and behavioral toxicology. 
One unifying superstructure among all subdivisions of toxicology is the duration of the 
study. Most studies fall under one of three categories: acute, sub chronic, or chronic. 
History of genetic toxicology: 
Genetic toxicology evolved from the initial studies of gene mutability demonsfrated 
first by Muller in 1927 using radiation followed almost 20 years later by Auerbach et 
al, 1947 using chemicals. Both of these investigators conducted their studies using 
submammalian species, but within the next 20 years, genetic changes m animals 
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induced by radiation and chemicals were demonstrated by Cattanach (1966) and 
Russell (1951) at Oak Ridge. This work created the awareness that some of the 
"hereditary" diseases observed in human populations might be environmental in origin 
(Bridges et al., 1979 & Russell, 1977). Proof in the early 1940s that deoxyribonucleic 
acid (DNA) is the hereditary material and the subsequent elucidation of its primary, 
secondary and tertiary structures by Watson and Crick in the early 1950s, opened up 
new avenues of research into the mechanisms of mutagenesis. 
The period of time from 1953 to 1968 might be considered the first "Golden Era" of 
molecular genetics. During this time, much of the basic information was developed 
regarding DNA structure and replication, the genetic code, mechanisms of protein 
synthesis, and DNA repair processes. Cell biologists and biochemists and 
microbiologist reigned over this Golden Era, and several received Nobel prizes for 
their contributions. The foundation established by the scientists in the first "Golden 
Era" has led to a second burst of information and technology associated with directed 
manipulation of genetic elements, often referred to as genetic engineering. This new 
era started in 1978 with the reports of gene transfer and expression between unrelated 
organisms (Guarente et al, 1980 & Itabura et al., 1977). 
Genetic toxicology was recognized as a discipline in 1969 when the Environmental 
Mutagen Society was founded under the leadership of Dr. Alexander HoUaender and 
several other geneticists who were concerned about the potential genetic impact 
associated with the proliferation of man made chemicals in the environment. The 
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concept of genetic toxicology was clearly consistent with the intense concern for 
environmental protection that prevailed at the time. 
Occurring simultaneously with the growing concern by geneticist over environmental 
mutagens were the reports from several independent groups of investigators showing a 
correlative relationship between mammalian carcinogens and mutagens (Ames, 1979; 
Bridges, 1976; Brusick, 1978; MaCann et al., 1975 & Sugimura et ai, 1976). Earlier 
attempts to support such a correlation experimentally failed because of the limitations 
inherent in the genetic assays available. The concept of mutagenic carcinogens was 
revitalized, however, following the introduction of procarcinogen activation using host 
mediated (Gabridge & Legator, 1969) and in vitro microsome activation systems 
(Mailing, 1971) developed from 1969 through 1971. The fulfillment of this relationship 
was the identification of mammalian cancer genes (oncogenes) and the demonstrated 
presence of mutafions in the activated forms of these genes (Reddy et al., 1982). 
Thus genetic toxicology has played a dual role in safety evaluation programs. One 
function is the implementation of testing and risk assessment methods to define the 
impact of genotoxic agents found in the environment and whose presence may alter the 
integrity of the human gene pool. The second funcfion is the application of the genetic 
methodologies to the detection and mechanistic understanding of carcinogenic 
chemicals. In this latter regard, genetic toxicology has been applied as a front - line 
screen for potential carcinogens. Genetic toxicology has continued to grow as a 
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specialty area of toxicology, with significant influence on overall chemical safety 
evaluation. 
Agents that produce alterations in the nucleic acids and associated components at sub 
toxic exposure levels, resulting in modified hereditary characteristics or DNA 
inactivation, are classified as genotoxic and the phenomenon is known as genotoxicity. 
Genotoxic substances usually have common chemical or physical properties that 
facilitate interaction with nucleic acids. In fact, the universalities of the target molecule 
are the key to the discipline of genetic toxicology. Derivation of the term genotoxic 
though is found in a publication by Ehrenberg et al, 1984, a report of the international 
commission for protection against environmental mutagens and carcinogens 
(ICPEMC) provided a more detailed definition of the term genotoxic and emphasized 
that categorization of a chemical as genotoxic is not a priori indication of a health 
hazard. The term is a general description meant to distinguish chemical that have an 
affinity for direct DNA interactions from those that have not. Most of the chemicals 
have already exhibited carcinogenic and mutagenic properties in animal models and in 
a variety of short term tests (lARC, 1982, Wynder, 1980). 
Genotoxic substances or mutagens are not necessarily carcinogenic (Nestman, 1986). 
Mutagens lead to the chromosomal mutations can be harmful, beneficial, or have no effect. 
If they occur in cells that make eggs or sperms, they can be inherited; if mutations occur in 
other types of cells, they are not inherited; if mutations occur in other types of cells they 
are not inherited, certain mutations may lead to cancer or other diseases. Chromosomal 
mutations can lead to structural and numerical changes in chromosomes 
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Some structural changes are:-
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1. Chromosomal deficiency: - It involves the loss of a part of chromosome. 
2. Chromosomal duplication: - It involves addition of a part of a chromosome. 
3. Chromosomal inversion: - It involves a reverse order of the genes in a part of 
chromosomes. Inversion may be classified into two types: 
a. Pericentric - include the centromere 
b. Paracentric - do not include the centromere 
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(includes centromere) 
b) Paracentric inversion 
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4. Chromosomal Translocations: 
It involves exchange of segments between non homologous chromosomes. 
5. Types of chromosomal aberrations: 
Aberration can be divided into two main groups, chromosome (isochromatid) and 
chromatid. Chromosome-type aberrations affect both chromatids, while chromatid-type 
aberrations affect only one. Within each group, there are a number of different types. In 
many instances a particular aberration can be readily identified, while some of the 
more common misinterpretations are given below. Most chemicals will rarely induce 
chromosome-type aberrations at the first metaphase post- treatment. 
20 
a) Pericentric inversion 
(includes centromere) 
b) Paracentric inversion 
(does not include centromere) 
A 
B 
C 
H" 
E 
F 
G 
H 
^ 
-d 
d 
3 ^ 
A 
B 
C 
J 
3 
m 
1 
G 
H 
A 
M 
c 
D 
E 
F 
G 
~H 
^ ^ 
^ 
. 
KJ 
n 
ffj 
A 
a 
» "> 
H 
E 
F 
~G^ 
H 
4. Chromosomal Translocations: 
It involves exchange of segments between non homologous chromosomes. 
5. Types of chromosomal aberrations: 
Aberration can be divided into two main groups, chromosome (isochromatid) and 
chromatid. Chromosome-type aberrations affect both chromatids, while chromatid-type 
aberrations affect only one. Within each group, there are a number of different types. In 
many instances a particular aberration can be readily identified, while some of the 
more common misinterpretations are given below. Most chemicals will rarely induce 
chromosome-type aberrations at the first metaphase post- treatment. 
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I. Gap or break: 
If a short unstained region on one chromatid, or misalignment of the proximal and 
distal parts of a chromatid with an unstained region, are observed, classification into 
gap or break respectively is unequivocal. Between these two, it can be difficult to 
determine the nature of the aberration. For this reason, it is important to use a rule- of-
thumb and adhere to it. One such system is to regard an unstained region less than the 
width of a chromatid as a break. 
II. Dicentrics: 
Dicentric chromosomes are uncommon in chemically-treated cultures, 
particularly with a harvesting time of about 1.5 cell cycles, although they are often seen 
in irradiated cultures. Dicentrics are characterized by the presence of two clearly 
defined centromeres. Confusion may occur when chromosome arms overlap and 
present the appearance of a second centromere. They can usually be differentiated by a 
darker stained region where the chromatids cross each other. 
III. Isochromatid gaps: 
Secondary constrictions, the centromere being the primary constriction, may result in 
an unstained region that may be confused with an isochromatid gap. A good example 
of this is on the long arm of the X chromosome in the Chinese hamster. 
IV. Satellite association: 
In man, the nucleolar organizer regions (NOR) are found in satellite regions (as distinct 
from the satellite DNA) on the short arms of chromosomes 13, 14, 15, 21 and 22 (the 
acrocentric chromosomes). Quite commonly, the satellite lie in apposition in 
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metaphase spreads, with random association between two or more of these 
chromosomes. This can lead to two misinterpretations. Firstly, if they are very close, 
they may be counted as one instead of two chromosomes. Secondly, the appearance 
may be sufficiently bizarre for the phenomenon to be mistakenly recorded as some type 
of aberration. 
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Some numerical chromosomal changes are: 
1. Aneuploidy: 
It means presence of chromosome number which is different than a multiple of 
basic chromosome number. 
2. Euploidy: 
It means presence of one or more of full sets of chromosomes in an organism. 
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Classification: 
Chromosomal abnormalities are classified and diagnosed cytogenetically either as 
autosomal abnormalities or as sex chromosomal abnormalities depending upon the 
nature of the chromosomal complement involved. 
Autosomal Chromosome abnormalities: 
Many syndromes result from complete trisomies or due to translocations of portions of 
either short or long arm, and deletions of the various chromosomes, Few common 
clinical entities observed are: 
1. Down syndrome ( Trisomy 21/ Trisomy G/ Mongolism) 
1. Trisomy 18 (Edward syndrome/Trisomy E) 
2. Trisomy 13 (Patau syndrome/ Trisomy D ) 
Sex chromosome abnormalities: 
Sex determination in humans is controlled by the X and the Y chromosomes. The 
female has two X chromosomes, and the male has one X and one Y. The Y 
chromosome is among the smallest of the 46 chromosome (G series), and its major 
function seems to be related to male sex determination. In contrast, the X is one of the 
largest chromosomes (C series) and contains hundreds of genes, most of which have 
nothing to do with sex determination. Few sex chromosome abnormalities are:-
1. Turner Syndrome (Turner's syndrome/ Bonnevie - Ullrich Syndrome) 
2. The Triple X syndrome (47,XXX) 
3. Klinefelter syndromes (Klinefelter's syndromes; 47,XXY) 
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4. The 47,XYY syndrome 
Chromosome deletion and deletion syndromes: 
Syndromes resulting from loss of parts of chromosomes are studied in different cases 
of karyotypic abnormalities. It includes deletions of whole or part of the chromosomes, 
autosomes as well as sex chromosomes, e.g.-
1. 5p-Deletion (cri du chat syndrome) 
2. 4p-Deletion (Wolf- Hirschhom syndrome) 
DNA Damage: 
DNA damage is the major cause of cancer and many other diseases (Haitt et al, 1974; 
Ames, 1979). The human disorders like ataxiatelangiectasia, Bloom's syndrome and 
Franconis anemia are genetic diseases characterized by an increased susceptibility to 
cancer (Walker et al, 1985). According to advance studies, main cause of death and 
disability is the damage to DNA by environmental mutagens (Cairns 1975). 
Mutagenesis and carcinogenesis is primarily initiated because of the reaction of 
mutagens with DNA and also their reaction with certain amino acids in proteins. 
Nicotine expresses significant direct genotoxic effects in human target cells in vitro 
(Kleinsasser,^ /' al, 2005). Dyeing, printing and textile industries discharge effluents in 
the environment and are found to be mutagenic during Ames and salmonella 
/microsome mutagenicity assays (Mathur et al, 2005). Alcohol and smoking resuhs in 
increased frequency of sister chromatid exchange (Karaoguz,e? a/. ,2005). 
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Oxidative Damage 
[tivated oxygen agents that generate free oxygen radicals such as ionizing radiation induce 
Inlm^rous lesions in DNA that cause deletions, mutations and other lethal genetic effects. 
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y?ll drugs are capable of producing beneficial as well as harmful effects. The nature of 
these harmful effects falls into two mechanistic categories: 
1. Effects related to the principal pharmacological action of the drug. 
2. Effects unrelated to the principal pharmacological action of the drug. 
It is also important to categories harmful effect in terms of their severity, and to 
distmguish between those that cause a temporary inconvenience or discomfort, and 
those that can lead to permanent disability or even death. 
Drugs may have properties that can be harmful to people taking them (drug toxicity). 
These may be so undesirable that they greatly limit the therapeutic usefuhiess of a 
given drug. Following table summarizes a scheme for the classification of drug induced 
toxicities. It is based partly on a scheme proposed by Rosenheim, but an effort has been 
made to deal more completely with the fundamental mechanisms involved. There are 
two major subdivisions under the category "primary toxic effects". The first is related 
to the therapeutic or pharmacologic properties of the drug, whereas the second deals 
with adverse or toxic effects unrelated to the pharmacologic properties. 
29 
Classification of drug-induced toxic reactions 
I. Primary toxic effects: 
A. Exaggerated pharmacologic effect 
1. Occurs with drug overdose. 
2. Occurs with therapeutic doses if individual is hyper reactive (hyper-
susceptible, intolerant) to drug. 
3. Indirect consequence of primary drug action. 
B. Adverse effect unrelated to pharmacologic therapeutic effect. 
1. Occurs with drug over dosage. 
2. Occurs with therapeutic doses. 
3. Occurs with therapeutic doses with individual is hyper- reactive (hyper-
susceptible, intolerant) to drug. 
II. Undesirable side effects 
Undesirable pharmacologic effect that accompanies the primary drug action 
1. Occurs with therapeutic doses. 
III. Allergic Reactions 
Effect based on immunologic reaction (antigen antibody reaction) 
1. Occurs in sensitized individual 
2. Occurs with therapeutic or sub therapeutic doses. 
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IV. Idiosyncratic Reactions 
Unexpected or unpredictable reaction, dissimilar from known pharmacologic 
or adverse effects attributable to the drug 
1. Depends on the personal characteristics of the individual 
2. Occurs in smaller number of individuals 
3. May be attributable to the genetic status of the individual 
V. Physical dependence 
Altered physiologic state resulting in abstinence syndrome when drug in 
discontinued. 
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Jill drug used for malaria therapy or prophylaxes have almost common adverse effects, 
in addition to rare, mild-to-severe and /or sometimes fatal adverse effects. 
Chloroquine: 
Chloroquine is effective against P.vivax, P.ovale, P.malariae, and drug-sensitive 
P.falciparum, it is used for treatment or as prophylaxis. Chloroquine is usually well 
tolerated. Mild side effects, such as nausea and headache, may occur. 
Chloroquine-induced pruritus is thought to involve a complex interaction between the 
host, the parasite and the drug. Some genetic markers, notably haemoglobin genotype 
and G6PD,, have been found to be associated with chloroquine induced pruritus. Acute 
toxicity is most frequently encountered when therapeutic or high doses are 
administered rapidly by parenteral routes. Chloroquine doses of more than 5 gm given 
parenterally are usually fatal. Parenteral admmistration can cause hypotension, cardiac 
depression and arrhythmias (Bacon et al, 2000). 
Primaquine: 
Primaquine is often administered for the hypnozoite stage of P. vivax and P. ovale to 
prevent relapse and after departure from a malaria-risk area for prophylaxis. 
Therapeutic or higher doses of primaquine can cause hemolytic anemia or fatal 
hemolysis in G6PD-deficient persons. High doses (60-240 mg of primaquine daily) 
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accentuate the abdominal symptoms and cause methemoglobinemia in most subjects 
and leucopenia in some. 
Mefloquine: 
Mefloquine is structurally similar to quinine. It is used for treatment or prophylaxis of 
drug-resistant malaria. It may have cardiac depressant effects and antifibrillary activity, 
and may result in marked gastrointestinal or CNS adverse effects. The higher incidence 
of adverse effects observed when the drug is used at the higher doses needed for 
malaria treatment implies a dose effect (Philips and Kuile, 1995). It is contraindicated 
in hypersensitivity; epilepsy or seizure disorder; severe psychiatric disorder, and in 
patients with a diagnosis or treatment for irregular heartbeat. 
Amodiaquiine: 
Hepatitis and agranulocytosis were seen in patients taking amodiaquine for 
prophylaxis, and the drug is no longer recommended for this indication. The 
quinoneimine is highly reactive and heptenates proteins, generating antigen to which 
an immune response may be important in the generation of organ damage (Winstanly 
et al, 200A) 
Quinine: 
Quinine sulphate is used for malaria treatment only, has no role in prophylaxis and is 
used with a second agent in drug-resistant P. falciparum. Hemolytic anemia may occur 
in patients with G6PD deficiency. Quinine is associated with a triad of dose-related 
toxicities when it is given at full therapeutic or excessive doses, e.g. cinchonism, 
hypoglycemia, and hypotension. Quinine has a a-adrenergic blocking effect, and 
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hypotension may occur as a result of vasodialation, myocardial depression, or 
dysrhythmia(Bateman et a/,1985). Mild forms of cinchonism, e.g. tinnitus, high-tone 
deafness,visual disturbances, headache, dysphoria, nausea, vomiting and postural 
hypertension occur frequently and disappear soon after the drug is withdrawn. 
Artemisinin and its derivates: 
Artemether-lumefantrine, a new fixed-dose oral antimalarial which combine the fast 
onset of action of artemether (an artimisinin derivative) in terms of parasitic clearance 
with the high cure rate of lumefantrine in the treatment of uncomplicated P. falciparum 
malaria. The most commonly reported AEs following Artemether-lumefantrine therapy 
are abdominal pain, anorexia, nausea, vomiting, diarrhea and CNS involvement 
(Headache and dizziness). Pruritus and rash were reported by <20% of patients. 
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'Two types of antimalarial drugs were selected for the cytogenetic evaluation in the present 
investigation. Of these one is pyrimethamine/sulfadoxine and the other is chloroquine. 
PYRIMEl HAMME/SULFADOXINE: 
DESCRIP'nON 
Fansidar is an antunalarial agent, each tablet containing 500 mg Nl-(5, 6- dimethoxy -
4- pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2, 4- di amino - 5-(P-
chlorophenyl) - 6-ethylpyrimidine (Pyrimethamine). Each tablet also contains 
cornstarch, gelatin, lactose, magnesium stearate and talc. 
Fansidar is an antifolic agent (Laurence et ah, 1997; Sims et al., 2002) and it has been 
reported to affect folate dependent DNA-synthesis (Rosenthal and Goldsmith, 2001). 
The two components of Fansidar, sulphadoxine and Pyrimethamine, competitively 
inhibit tlie en2yme dihydrofolate reductase which converts dihydrofolate to 
tetrahydrofolate (Krishaswamy and Teoh, 1980). The blockade of dihydrofolate reductase 
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enzyme by pyrimethamine prevents synthesis of folic acid (FA) in the cells (Krishaswamy 
and Tech, 1980). The prevention of biosynthesis of folic acid inhibits DNA replication and 
amino acid synthesis (Laurence and Benett, 1980; Waxman and Herbert, 1969). This 
inhibition can lead to stmctural chromosome defects such as gaps, breaks, acentric 
fragments, etc. Also, it can cause the development of fragile sites, which are points on 
chromosomes that usually appear as non staining chromosomes or chromatid gaps. These 
regions may be involved in chromosome breakage and recombination events (Glover and 
Stein, 1988). 
CHLOROQUINE: 
DESCRn»TION 
Chloroquine is a 4-aminoquinoline that has marked and rapid schizonticidal activity 
against all infections of P. malariae and P. ovale and against chloroquine-sensitive 
infections of P. falciparum and P. vivax. It is also gametocytocidal against P. vivax, P. 
malariae and P. ovale as v^ 'ell as immature gametocytes (stages 1-3) of P. falciparum. 
It is not active against intrahepatic forms, and should therefore be used with 
primaquine to effect radical cure of P. vivax. and P. ovale . The popularity of 
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chloroquine [7-chloro-4-(4-diethylamino-l-methylbutylamino) quinoline, CHQ] for 
malaria treatment in many Third World countries emanates from it being cheap, widely 
available, relatively well tolerated, and having a rapid onset of action. CHQ is 
commonly sold as an over-the-counter medication and is also used as an anti-
inflammatory drug in the treatment of rheumatoid arthritis, discoid lupus 
erythematosus and amoebic hepatitis. CHQ inhibits pro-inflammatory cytokine release 
into human v^ 'hole blood and may be of therapeutic benefit not only during chronic 
inflammation, but also in diseases that are related to bacteria-induced inflammation. 
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Cytogenetic abnormalities can essentially be studied in any cycling cell population, or 
in any cell population that can be stimulated by a mitogenic agent to cycle. In animal 
there are several cell types that fit these criteria, but for humans there are to all intents 
and purposes, only two types that are practically suitable. These are the bone marrow 
ceils, which are a cycling population, and peripheral lymphocytes, which are normally 
non cycling, but can be stimulated to enter the cell cycle by culturing in vitro with a 
mitogen such as phytohaemagglutinin (PHA). Because of the ease of obtaining blood 
samples in contrast to taking bone marrow samples, the majority of experiments on the 
induction of chromosome aberrations in human have been done with the lymphocytes 
assay. 
Human chromosome preparation and karyotyping: 
Metaphase spread diagnosis is the main source of studying chromosomal aberrations 
from abnormal karyotype. It is also needed perhaps for extending specified prenatal 
genetic counseling. A brief approach to the different types of laboratory tests 
performed, diagnosed and their expected results are highlighted in this study. 
The misconception of human diploid chromosome number being 48, and the sex 
determining mechanism of XX/XY method being identical with that of Drosophila 
melanogaster was confirmed completely in 1956, with the discovery of diploid 
chromosome number in the embryonic lung cells as 46 (Tjoe and Levan, 1956), 
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followed by the same diploid ctiromosomal count in other human tissue like 
spermatocytes. Interesting and diagnostic was the detection of unbalanced diploid 
chromosomal numbers as autosomal trisomy (Lejune et al, 1959), 45X monosomy 
(Ford et al, 1959), and 47XXY (Jacobs et al, 1959). The cell culture techniques by 
Moorehead et al. (1960) using lymphocyte culture were employed with some 
modification for the human chromosome studies. The development of chromosome 
methodology is the result of added innovations from time to time viz. use of tissue as 
monolayers or suspension, use of colchicines as a major spindle arresting agent, 
hypotonic treatment, fixation of cells in culture, and flame and air drying methods for 
slide preparations (Makino 1975, Hsu 1979). Thus, history of human cytogenetics can 
be classified into four eras: dark age (before 1952), hypotonic era (1958), trisomy era 
(1969) and banding era (1970 onwards). 
METHODOLOGY: 
Human Lymphocyte Culture: 
Chromosomal aberrations resulting due to some antimalarial drugs were observed 
using human lymphocyte culture as per the method of Moorehead et al, 1960. 
Reagents 
Culture Medium: 
Medium has been used as an essential component for establishing lymphocyte 
culture/tissue culture (Paul 1985) for chromosomal preparations and other biochemical 
studies. Cytogenetic preparations of chromosomes required the use of synthetic media 
depending on the design of culture. Two types of synthetic media were employed: (i) 
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salt solution- for collection and short term survival, while (ii) complete media- for the 
growth and maintenance. Balanced salt solution (Normal saline), trypsin solution 
(versene solution for cell suspension from primary biopsy), stock solution (generally 
lOX, kept at -20°C in concentrated form), supplements (Natural media) like serum 
plasma etc are added to the complete media and stored for future use. 
Salt solution: Commercially available preparations were maintained as stocks (lOX) 
and stored at -20°C. Laboratory preparations of these solutions in required 
compositions (gm/ml) are stored. Widely used and available preparations include 
Hank's, Krebs, Dulbecco's, and Puck's. 
Complete media: Commercially available culture media include Eagle's minimum 
essential medium, TC-199, Parker-199, McCoy's 5(GIBC0) with L-glutamine, without 
sodium bi carbonate in powdered or aqueous form. 
Preparation of Stock Media: 
The medium used for the lymphocyte culture was RPMI 1640. Stock medium was 
prepared by dissolving 10 gm of powder (RPMI 1640 from GIBCO BRL, India) in 1 
liter of autoclaved distilled water. 
Working medium: 
The working medium was prepared by taking 87 ml of IX stock solution and adding 1 
ml of antibiotic solution 1% supplementing it with 12% fetal calf serum. The pH of the 
medium was maintained at 7.2 with the help of NaHCOs. The working medium was 
filtered and kept at 4°C in autoclaved bottles for further use. 
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Collection of blood sample: 
Peripheral blood from the healthy donors was taken fresh every time through veinal 
puncture, Heparin (500 ID/ml; Micro Lab) was used as anticoagulant. The tightly capped 
glass vials, were gently mixed and stored at 4°C for half an hour to separate red blood 
cells (RBCs) from plasma. 
Mitogenic agents: 
Phytohaemgglutinin (PHA), the most generally used mitogenic agent, is procured in two 
forms-M and P forms, where M was desiccated in micro form, without toxicity, while P as 
per manufacturers' specifications, was sterile and depolysaccharized form. P form was 
more potent to be used for culture preparations. 
Antibiotic solution: 
Antibiotic mixture including penicillin 10,000 unit/ml. Streptomycin 10 mg/ml and 
Amphotericin-B 0.025 mg/ml (Kibbutz Beit Haemek 25115 Israel) was used. It can be 
stored at -20°C. 
Hypotonic solution KCl: 
0.56% KCl (potassium chloride) solution pre warmed at 37°C was used. Sometimes 1% 
Sodium citrate solution can also be used. 
Colchicine: 
It is a mitotic poison. It arrests spindle fibers at metaphase stage. Colchicine is a highly 
poisonous natural product and secondary metabolite, originally extracted from plants of the 
genus Colchicum. (Autumn crocus, Colchicum autumnale also known as the "Meadow 
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saffron" Colchicum extract was first described as a treatment for gout in De Materia 
Medica by Padanius Dioscorides in the first century CE. The colchicines alkaloid was first 
isolated in 1820 by the two French chemists P.S. Pelletier and J.Caventon. It was later 
identified as a tricyclic alkaloid, and its pain relieving and anti-inflammatory effects for 
gout were linl<:ed to its ability to bind with tubulin. 
Biological function: 
Colchicine inhibits microtubule polymerization by binding to tubulin, one of the main 
constituents of microtubules. Availability of tubulin is essential to mitosis, and therefore 
colchicine effectively functions as a "mitotic poison" or spindle poison 1 mg colchicine 
powder is dissolved in 10 ml of autoclaved distilled water. It can be Stored at 2 to 5°C for 
several months. 
Fixative: 
Freshly prepared glacial acetic acid: methyl alcohol (1:3) was usually used. Other 
combinations that can be made include ethyl alcohol: glacial acetic acid (3:1, 2:1), acetic 
acid in 45^0-60%, distilled water or ethyl alcohol: glacial acetic acid: chloroform 
(100:16:50), Camoy's solution or ethyl alcohol 95%: acetic acid: formaldehyde 40% 
(6:2:l)-Tjio's fixative. 
Giemsa stain: 
Giemsa stain, named after Gustav Giemsa, an early malariologist, is used for the 
histopathological diagnosis of malaria and other parasites. It is a mixture of methylene blue 
and eosin. ITie stain is usually prepared from commercially available Giemsa powder. It is 
specific for the phosphate groups of DNA and attaches itself to regions of DNA where 
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there are high amounts of adenine-thymine bonding. Giemsa stain is used in Giemsa 
banding, corcimonly called G- banding, to stain chromosomes and often used to create a 
karyotype. It can identify chromosomal aberrations such as translocations and interchanges. 
Shelf Life and Storage: 
Giemsa stain solution has a shelf life of 2 years when stored unopened at +15°C - +25°C 
diluted solution is stable for one day. 
Giemsa stain (stock): 
1.0 gm Giemsa powder was mixed in 66 ml of glycerine and placed in 60°C over for 24 
hrs (one day) and then methanol is added. 
a.Working solution 1: 
1.25 ml of Giemsa stock is added in 1.5 ml of methanol in 50 ml of autoclaved distilled 
water. 
b. Working solution 2: 
5 ml of Giemsa stock is added in 45 ml of phosphate buffer solution. 
Sampling and culture: 
Tissue and cells used: 
Different tissues and cells were used to put up the culture. They include bone 
marrow (Hamerton 1971), fibroblasts, amniotic cells and leukocytes etc. 
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Sampling and culture setting: 
Sampling of peripheral blood is easiest, painless and also short term. Cells show 
mitotic activity after a lag period of 48 hours, increasing considerably due to 
mitogenic action of the used mitogens, Phytohaemagglutinin (PHA). 
Cultures were planted in previously cleaned and sterile chamber of laminar flow. All the 
necessary apparatus (culture vials, pipettes) were sterilized before use. About 0.4 ml of 
blood was transferred to a culture vial, already containing 5-7 ml of culture medium and 
0.2-0.3 ml of phytohaemagglutinin (PHA), under he sterile conditions of laminar flow. 
Then the vials were closed tightly and were put at 37°C for 72 hour in water bath. 
Harvesting the culture: 
0.15 ml of colchicine (2)iig/ml) was added to each vial 1 hr prior to harvesting to arrest 
the cells at metaphase stage. After 1 hour of colchicine's action in the medium, the 
cultures were taken out from the incubator and its content, after gently shaking was 
transferred to a centrifuge tube. The cells were spun down by centrifugation (10 min, 
1000 rpm) and the button of cells was saved by discarding the supernatant. The 
supernatant was discarded by pipetting out the media as little medium as possible over 
the cell button. (If there are any tough cell aggregates that cannot be dissociated, they 
should be removed prior to centrifugation). 
Hypotonic treatment (0.075 M KCl) was carried out for 10-20 minutes at 37°C and the 
cells recollected by centrifugation. Cells should be handled very gently following 
the hypotonic treatment. Any harsh treatment may rupture the cells leading to many 
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undesirable incomplete metaphases in the final preparation. To prevent undue 
damage to the cells, avoid passing the suspension through narrow tipped droppers 
or pipettes at this stage are avoided. The cell pellet was suspended in a 7 ml freshly 
prepared chilled fixative (3:1, methanol: acetic acid), which was added drop by drop 
using a Pasteur pipette while continuously shaking the pellet so as to avoid formation 
of clots. In order to ensure the proper fixation, the cells were kept suspended in the 
fixative at 4°C for a minimum period for 1-hour but preferably overnight. The 
contents, then, were again centrifuged at 1000 rpm for 10 minutes and the same two 
or three changes with fresh fixative were given before preparing the slide. 
Slide preparation: 
After giving final washing in the fixative, the cells were resuspended in 0.2 ml of 
fresh fixative. Slides were prepared by flame drying technique. Slides were washed 
clean and kept at 4 °C in distilled water. About 3-4 drops of cell suspension were 
dropped per slide with the help of Pasteur's pipette over the chilled, tilted slides 
maintaining a stretched hand distance between the slides and the pipette to get better 
spreading, and a brief exposure to the flame was given to dry the slides. Three 
drops/slide was generally enough to get a satisfactory cell count. The slides were kept 
in a slide box under dust free conditions for further use. The remaining cell suspension 
was transferred to a sterile eppendorf, para sealed, labeled and stored at 4°C. After 
one-hour slides were stained in 5% Giemsa stain in phosphate buffer (pH 6.8). 
Staining: 
Giemsa stain was used for staining metaphase chromosomes. 
4b 
Photography: Detectable and finely spread metaphase chromosome spots were analyzed 
under lOOX oil immersion, position of the desired spot was marked by reading scales over 
the microscope. Photographs were taken with an automatic digital camera attached in a 
Nikon microscope. 
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"Table I, II, III, IV, V & VI summarizes of the result of chromosomal aberration in 
human lymphocytes culture either exposed or non exposed to chloroquine. I have taken 
six subjects for the study. For each subject lymphocytes exposed to chloroquine, a dose 
dependent significant increase in clastogenic damage was found. Table I represents a 
summary of the results of chromosomal aberration in controlled cultured human 
lymphocytes. The total percentages of chromosomal aberrations were- Gaps 3.3%, 
Breaks + Rearrangements 6.6% in subject (A). Gaps 2.7%, Breaks + Rearrangements 
5.5% in subject (B). Gaps 4%, Breaks + Rearrangements 4% in subject (C). Gaps 2%, 
Breaks + Rearrangements 2% in subject (D). Gaps 6.5%, Breaks + Rearrangements 2% 
in subject (E). Table II depicts the results observed for chromosomal aberration at 5 ^1 
of concentration the values of chromosomal aberration were Gaps 11.7%, Breaks + 
Rearrangements 8.8% in subject (A).Gaps 14.5%, Breaks + Rearrangements 10.4% in 
subject (B). Gaps 12%, Breaks + Rearrangements 8% in subject (C). Gaps 7.14%, 
Breaks + Rearrangements 14.2% in subject (D). Gaps 10.5%, Breaks+ Rearrangements 
13% in subject (E) -. From the above it is clear that due to the exposure of drug at the 
concentration of 5 ^1 mitotic mdex is decreased and the no. of gaps breaks and 
translocations number is increased. Whereas the results of chromosomal aberration 
analysis were presented in table III at the concentration of 10 jil were Gaps 16%, 
Breaks + Rearrangements 20% in subject (A). Gaps 20.8%, Breaks + Rearrangements 
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16.6% in subject (B). Gaps 21%, Breaks + Rearrangements 15.7% in subject (C). Gaps 
16.6%, Breaks + Rearrangements 20.8% in subject (D). Gaps 13.1%, Breaks + 
Rearrangements 21% in subject (E). Table IV represents the results observed for 
chromosomal aberration at the concentration of 25 |il were Gaps 8%), Breaks + 
Rearrangements 36% in subject (A). Gaps 25%, Breaks + Rearrangements 21.4% in 
subject (B). Gaps 20%, Breaks + Rearrangements 28% in subject(C). Gaps 20.8%, 
Breaks + Rearrangements 25% in subject (D). Gaps 22.5%, Breaks + Rearrangements 
25% in subject (E), while Table V depicts the results observed for chromosomal 
aberration at the concentration of 50 [il were Gaps 32%, Breaks + Rearrangements 
28.5% in subject(A). Gaps 33%, Breaks + Rearrangements 26.5% in subject (B). Gaps 
20.8%, Breaks + Rearrangements 29.1% in subject (C). Gaps 25%, Breaks + 
Rearrangements 28% in subject (D). Gaps 23%, Breaks + Rearrangements 33.3% in 
subject (E). 
Table VI depicts the results observed for chromosomal aberration at the concentration 
of 100 n\ were Gaps 14.2%, Breaks + Rearrangements 57.2% in subject(A). Gaps 10%, 
Breaks + Rearrangements 60% in subject (B). Gaps 20%, Breaks + Rearrangements 
45% in subject (C). Gaps 25%, Breaks + Rearrangements 30% in subject (D). Gaps 
16.6%, Breaks + Rearrangements 33.3% in subject (E). Chioroquine shows a 
significant decrease in mitotic index at the highest dose. At 5|il dose, the percentage of 
total damaged cells increased to 22%. At the chioroquine dose of 100|il, the percentage 
of total damaged cells was 62.3%. The result reveals the fact that chioroquine is 
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comparatively less clastogenic which may be attributed to the mechanism of action of 
the drug. 
The result of chromosomal aberration in human lymphocytes culture either exposed or 
non exposed to pyrimethamine/sulphadoxine has been given in Table I, II, III, IV & V. 
For each subject lymphocytes exposed to PYR/SPD, a dose dependent significant 
increase in clastogenic damage was found. Table I represents a summary of the results 
of chromosomal aberration in controlled cultured human lymphocytes. The total 
percentages of chromosomal aberrations were - Gaps 2%, Breaks+ Rearrangements 0% 
in subject (A). Gaps 4%, Breaks + Rearrangements 2% in subject (B). Gaps 4%, 
Breaks + Rearrangements 4% in subject (C). Gaps 2.75%, Breaks + Rearrangements 
5.5% in subject (D). Gaps 2.9%, Breaks + Rearrangements 0% in subject (E). Table II 
depicts the results observed for chromosomal aberration at 1:20 ^g/ml of concentration 
the values of chromosomal aberration were - Gaps 11.7%, Breaks+ Rearrangements 
14.7% in subject (A). Gaps 10.7%, Breaks + Rearrangements 17.8% in subject (B), 
Gaps 6.8%, Breaks + Rearrangements 20.6% in subject (C). Gaps 10%, Breaks + 
Rearrangements 20% in subject (D). Gaps 16.6%, Breaks + Rearrangements 12.5%, in 
subject (E). From the above it is clear that due to the exposure of drug at the 
concentration of 1:20 i^ g/ml mitotic index is decreased and the no. of gaps, breaks and 
translocations number is increased. Whereas the results of chromosomal aberration 
analysis were presented in table III at the concentration of 3:60 |ig/ml were - Gaps 
12%, Breaks+ Rearrangements 40% in subject (A). Gaps 30%, Breaks + 
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Rearrangements 20% in subject (B). Gaps 15.3%, Breaks + Rearrangements 34.6% in 
subject (C). Gaps 13.3%, Breaks + Rearrangements 33.3% in subject (D) Gaps 10.7%, 
Breaks + Rearrangements 35.7% in subject (E). Table IV represents the results 
observed for chromosomal aberration at the concentration of 5:100 |ig/ml were - Gaps 
20%, Breaks + Rearrangements 30% in subject (A). Gaps 40%, Breaks + 
Rearrangements 20% in subject (B), Gaps 24%, Breaks + Rearrangements 36% in 
subject (C). Gaps 32%), Breaks + Rearrangements 32% in subject (D). Gaps 30%, 
Breaks + Rearrangements 32.6% in subject (E). Table V depicts the results observed 
for chromosomal aberration at the concentration of 10:200 |ig/ml were - Gaps 17.6%, 
Breaks + Rearrangements 47% in subject (A). Gaps 16.6 %, Breaks + Rearrangements 
50% in subject (B). Gaps 18.1%, Breaks + Rearrangements 45.5% in subject (C). 
Gaps 14.2%, Breaks + Rearrangements 57.1%, in subject (D) Gaps 0%, Breaks + 
Rearrangements 60% in subject (E). 
From the above data it is clear that there is a significant decrease in mitotic index at the 
highest dose as it seems toxic to the cells. Among the control cultures, the mean 
frequency of cells with total damaged cells was 5.4%. At 1:20 )Jg/ml dose, the 
percentage of total damaged cells increased to 29.5%. At the PYR/SPD dose of 10:200 
|ig/ml, the percentage of total damaged cells was 65.5%». 
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Chloroquine, a 4-aminoquinolone derivative and is commonly used for the chemo 
suppression and radical cure of malaria and is also used as an anti inflammatory drug in 
the treatment of rheumatoid arthritis (Titus et al.\9%9) and (Augustijns et al. 1993), 
discoid lupus erythematosus (Krishna et al 1996) and (Meinao et al. 1996) amoebic 
hepatisis (Abdi et a/. 1995). Chloroquine inhibits proinflammatory cytokine release into 
human w h^ole blood and may be of therapeutic benefit not only during chronic 
inflammation, but also in disease that are related to bacteria-induced 
inflammation(Karres et al. 1998). 
Chloroquine, well- known lysosomotropic agent, has long been used for the treatment 
of malaria and rheumatologic disorders. Chloroquine is rapidly and almost completely 
absorbed from the gastrointestinal tract. Chloroquine is extensively localized in the 
tissues of kidney, liver, lung and spleen and is strongly bound by melanin containing 
cells, such as those in the eyes and skin. In these tissues, it becomes concentrated in 
lysosomes particularly in such cells as those of the liver parenchyma. From all these 
sites it is slowly excreted and metabolized and may be present in tissues for months or 
even years after discontinuation of therapy (Bruce-Chwatt, 1986). The recommended 
dose for chloroquine is 10 mg base/kg followed by lOmg base/kg at 24 hour and 5 mg 
base/kg at 48 hour orally for uncomplicated malaria caused by P. vivax and P. ovale 
and 3.5 mg base/kg by i.m. or s.c. injection every 6 hour for 24 hour for severe malaria. 
51 
Chloroquine interferes with the activation of extracellular signal- kinase - mitogen 
activated protein kinase. While this is likely not the only cellular function affected by 
chloroquine; these data define a new molecular mechanism of action of this complex 
drug. Chloroquine interfered with the phosphorylation of ERK in several different 
cellular systems without reducing cellular levels of ERK. Rather, chloroquine appeared 
to increase total ERK levels as measured by western blotting, consistent with previous 
studies showing that this drug can reduce proteolysis. (De Feo et A/. 1994) and 
(Blagosklonny e/fl/., 1999). 
Chloroquine induce DNA strand breaks and oxidized Purine and Pyrimidine bases in 
mammalian cells. The malaria lacks the de novo Purine biosynthetic pathway and 
starvation of Purines is known to cause Purineless death in cultured cells. The most 
extensively studied enzyme of the salvage pathway is hypoxanthine-guanine-xanthine 
phosphoribosyltransferase [HGPRT]. Malaria parasites derive their pyrimidine 
nucleotides through a de novo pathway. They cannot utilise pre-formed pyrimidine 
nucleosides. Mammalian cells are capable of de novo and salvage pathways. The 
salvage enzymes (uridine kinase and thymidine kinase) are absent in the parasite. The 
de novo enzymes are carbamoyl phosphate synthase, aspartate transcarbamylase, 
dihydroorotase, dihydroorotate dehydrogenase (DHODase), orotate phosphoribosyl 
transferase and orotidine 5'-phosphate decarboxylase (Biagini et al, 2003) 
Thymidylate synthase (TS) is linked to dihydrofolate reductase. It is also an established 
target for antimalarial chemotherapy. Since TS is a highly conserved protein, selective 
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inhibitors may be difficult to design. An alternative strategy could be the combination 
of an effective TS inhibitor and a nucleoside that can be utilised by the host. N^-N^^-
methylene tetrahydrofolate analogues, which inhibit TS without being metabolised into 
the nucleotide pool, are considered attractive alternatives (Nduati et al, 2005). Such 
analogues need to be explored further. 
Chloroquine has been shown to interfere with some biochemical process, including 
inhibition of cytochrome 450 mediated oxidation reactions (Farombi and Emerole, 
1998; Farombi et al; 2000) and induction of oxidative stress in animals (Magwere et al; 
1997; Farombi et al; 2001) and ocular oxidative stress (Toler, 2004). 
Oxidative stress is an important mechanism for destruction of malaria and other 
intracellular parasites. It is caused by an imbalance between the production of reactive 
oxygen and a biological system's ability to readily detoxify the reactive intermediates 
or easily repair the resulting damage. All forms of life maintain a reducing 
environment within their cells. This reducing environment is preserved by enzymes 
that maintain the reduced state through a constant input of metabolic energy. 
Disturbances in this normal redox state can cause toxic effects through the production 
of peroxides and free radicals that damage all components of the cell, including 
proteins, lipids, and DNA. In intraerythrocytic-stage malaria, parasites encounter 
reactive oxygen species produced either by themselves or by the erj^ throcyte or host 
immune cells. To prevent oxidative stress, the parasite has its own battery of defence 
tactics and produces its own antioxidant enzymes. The malaria parasite contains three 
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antioxidant enzymes: superoxide dismutase (SOD), glutathione peroxidase (GPx) and 
catalase. The parasite's antioxidant defence could therefore be a potential target for 
antimalarial chemotherapeutics. Chloroquine was also recently demonstrated to 
mediate oxidative stress and affect antioxidant enzymes in humans (Farombi et al, 
2003). Furthermore, chloroquine has been shown to activate tyrosine kinase and 
protein kinase C to induce p38 mitogen activated protein kinase, which subsequently 
synthase and nitric oxide production (Chen et al, 2005), nitric oxide mediated 
inhibition of endothelial cell proliferation. (Ghigo et a/., 1998) 
Reactive oxygen species (ROS) which are produced by the induction of oxidative 
stress, such as hydrogen peroxide, superoxide and hydroxyl radical are products of 
oxygen metabolism in all aerobic organisms. ROS are generated as a result of energy 
production from mitochondria (from the electron transport chain), as part of an 
antimicrobial (Weiss et al, 1982) or antiviral (Griot et A/.,1989) response, as well as 
detoxification reactions carried out by the cytochrome P-450 system (Scholz et 
a/.,1990, Cederbaum et al, 1989). Environmental agents such as ultraviolet light, 
ionizing radiation, redox chemicals and cigarette smoke also readily generate ROS. 
The antioxidant defense system in most cells is composed of two components, the 
antioxidant enzymes component which includes enzymes such as superoxide 
dismutase, catalase and glutathione peroxidase, and the low molecular weight 
antioxidants component that includes vitamins A and E, ascorbate, glutathione and 
thioredoxin. These substances are the body's natural defense against endogenous 
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generated ROS and other free radicals, as well as ROS generated by external 
environmental factors. Oxidative stress occurs when the production of ROS exceeds 
the body's natural antioxidant defense mechanisms, causing damage to biomolecules 
such as lipids, proteins and DNA. 
Oxidative damage to DNA is a result of interaction of DNA with reactive oxygen 
species (ROS), in particular the hydroxyl radical. Superoxide and hydrogen peroxide 
are normally not reactive towards DNA. However, in the presence of ferrous or 
cuprous ion (the Fenton reaction), both superoxide and hydrogen peroxide are 
converted to the highly reactive hydroxyl radical. Hydroxyl radical produces a 
multiplicity of modifications in DNA. Oxidative attack by OH radical on the 
deoxyribose moiety will lead to the release of free bases from DNA, generating strand 
breaks with various sugar modifications and simple a basic (AP) sites. In fact, one of 
the major types of damage generated by ROS is AP site, a site where a DNA base is 
lost. 
Chloroquine is also responsible for the induction of oxidative stress (Magwere et al, 
1997; Farombi et al, 2001) resulting due to the production of reactive oxygen species 
which causes damage to the genetic material and induces DNA strand breaks. High 
doses of chloroquine increases cellular level of reactive oxygen species which leads to 
oxidative stress and ultimately oxidative DNA damage. /x.-^'-' ^ ^ ^ ''^  •^? 
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(Fansidar is an antifolic agent (Laurence et al., 1997; Sims et al, 2002) and it has been 
reported to affect folate dependent DNA-synthesis (Rosenthal and Goldsmith, 2001). 
The two components of Fansidar, sulphadoxine and Pyrimethamine, competitively 
inhibits two enzymes in the folate synthesis pathway-dihydropteroate synthetase and 
dihydrofolate reductase respectively, that catalyses the conversion of dihydrofolate to 
tetrahydrofolate, and this impairs DNA synthesis(Ouellette, 2001;Roper et al.,2003 ).In 
the same respect, Fansidar was found to have an inhibitory effect on lymphocyte 
transformation in vitro, whereas this inhibition was attributed to suppression of DNA 
synthesis (Bygbjerg et al., 1986).Thus, DNA synthesis inhibition has been suggested to 
be an indirect way for inducing genetic damage, the increased genotoxicity usually 
occurring at a concentration range of toxic doses (Galloway et al., 1998). The probable 
mechanism of antifolate- induced mutation has been attributed to nucleotide precursor 
pool imbalance of mammalian cells to result in deoxyuridine misincorporation into 
DNA (Veigl et al., 1991). In addition, deoxyuridine misincorporation or pool 
imbalance-induced replication defects may also underline increases in SCE as seen in 
antifolate- treated cells and fragile sites in human chromosomes. Folate deficiency is 
known to induce chromosomal aberrations (CA) and fragile site expressions (Kunz, 
1982 and 1988). 
The antimicrobial agent pyrimethamine is a folic acid antagonist (Waxman and 
Herbert, 1969; Webster, 1985) and by inhibition of folate reductase enzyme inhibits 
replication by preventing the formation of thymidilate which is used in DNA synthesis 
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(Waxman and Herbert, 1969 Dipelema, 1971; Meyers et a/., 1974; Dyke ,1982).As a result, 
lesions in the DNA molecule are produced and consequently gap, breaks and 
rearrangements are formed(Waxman and Herbert, 1969).Such breakage can lead to SCEs, 
deletions and translocations under appropriate conditions(GIover and Stein, 1988). In 
support of this conclusion it is known that folic acid deficient medium significantly 
increases the expressions of spontaneous chromosome breakage (Wekemans et al, 1983) 
and those inhibitors of DNA synthesis increase chromosome breakage (Moore and 
Hodgson, 1983). The suggested mechanism by which pyrimethamine causes structural 
chromosomal aberrations, fragile sites and sister chromosome exchange is presented in 
flow charts. 
According to this mechanism, when PYR enters into the cell it causes inhibition of DHFR 
enzyme. Due to the inhibition of this enzyme, tetrahydrofolate can not be formed from 
dihydrofolate. This inhibition may prevent the synthesis of thymidilate and purines with a 
consequent depletion in the dNTP pool. This either causes cell death because DNA cannot 
be synthesized and/or errors occur during DNA synthesis. These errors in DNA synthesis 
cause lesions in DNA and lead to the formation of structural chromosomal aberrations, 
fragile sites, and SCEs increase of the dosage of PYR/SPD given to the medium. It is 
observed that the most important increase is in the number of gap, break and acentric 
fragments. In conclusion, our study shows that pyrimethamine/sulfadoxine is a clastogenic 
chemical inducing various structure abnormalities in human chromosomes. 
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